| CTSH |
Report |
Revenue (Q2 2026) |
IN-LINE |
pred ~$5.50B vs. cons $5.487B |
MEDIUM |
| CTSH |
Report |
Adj. EPS (Q2 2026) |
BEAT |
pred ~$1.42 vs. cons $1.378 |
HIGH |
| CTSH |
Report |
Bookings/ACV (Q2 2026) |
IN-LINE |
pred ACV modestly positive vs. flat in Q1; TTM bookings ~$29-30B vs. cons $29.3B |
MEDIUM |
| CTSH |
Guide |
Q3 2026 Revenue (Q3 2026) |
BETTER |
guide ~$5.55-5.65B vs. cons $5.493B |
MEDIUM |
| CTSH |
Guide |
FY 2026 Revenue (FY 2026) |
UNCHANGED |
guide maintained +4.0%-+6.5% CC vs. cons $22.289B |
HIGH |
| CTSH |
Guide |
FY 2026 Adj. EPS (FY 2026) |
UNCHANGED |
guide maintained $5.63-$5.77 vs. cons $5.704 |
HIGH |
| CTSH |
Guide |
Demand tone / ACV (Forward) |
UNCHANGED |
ACV modestly positive; H2 recovery on track; discretionary still 1-2 quarters away |
MEDIUM |
| CTSH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| CTSH |
Return |
5-day cumulative residual |
-5.0% (FADE) |
FADE — sell-side models implied H2 math as back-end loaded; short covering provides partial floor but does not reverse; estimates drift lower on implicit H2 cut |
MEDIUM |